Пређи на садржај

Volinanserin

С Википедије, слободне енциклопедије
Volinanserin
IUPAC ime
(R)-(2,3-dimetoksifenil)-[1-[2-(4-fluorofenil)etil]-4-piperidil]metanol
Identifikatori
CAS broj139290-65-6 ДаY
ATC kodnone
PubChemCID 5311271
IUPHAR/BPS185
ChemSpider4470782
UNIIEW71EE171J ДаY
ChEMBLCHEMBL74355
Hemijski podaci
FormulaC22H28FNO3
Molarna masa373,46 g/mol
  • c3cc(F)ccc3CCN(CC2)CCC2C(O)c(c1OC)cccc1OC

Volinanserin (MDL-100,907) je visoko selektivan antagonist 5-HT2A receptor. On je u širokoj upotrebi u naučnim istraživanjima za istraživanje funkcije 5-HT2A receptora.[1][2][3] Volinanserin se isto tako ispituje kao potencijalni antipsihotik, antidepresiv i tretman za insomniju.[4][5][6]

  1. ^ Schmidt CJ, Fadayel GM, Sullivan CK, Taylor VL (1992). „5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine”. European Journal of Pharmacology. 223 (1): 65—74. PMID 1362159. doi:10.1016/0014-2999(92)90819-P. 
  2. ^ Herth MM, Kramer V, Piel M, Palner M, Riss PJ, Knudsen GM, Rösch F (2009). „Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET”. Bioorganic & Medicinal Chemistry. 17 (8): 2989—3002. PMID 19329329. doi:10.1016/j.bmc.2009.03.021. 
  3. ^ Nic Dhonnchadha BA, Fox RG, Stutz SJ, Rice KC, Cunningham KA (2009). „Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model”. Behavioral Neuroscience. 123 (2): 382—96. PMID 19331461. doi:10.1037/a0014592. 
  4. ^ Offord SJ, Wong DF, Nyberg S (1999). „The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action”. Journal of Clinical Pharmacology. Suppl: 17S—24S. PMID 10434243. 
  5. ^ Marek GJ, Martin-Ruiz R, Abo A, Artigas F (2005). „The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine”. Neuropsychopharmacology. 30 (12): 2205—15. PMID 15886717. doi:10.1038/sj.npp.1300762. 
  6. ^ Teegarden BR, Al Shamma H, Xiong Y (2008). „5-HT(2A) inverse-agonists for the treatment of insomnia”. Current Topics in Medicinal Chemistry. 8 (11): 969—76. PMID 18673166. doi:10.2174/156802608784936700. 

Spoljašnje veze

[уреди | уреди извор]